According to the Securities Times APP, biomedical concept stocks rebounded across the board, as of the deadline, Frontage (01521) rose by 14%, to 0.57 Hong Kong dollars; Pharmaron (03759) rose by 12.59%, to 14.84 Hong Kong dollars; Tigermed (03347) rose by 11.11%, to 38 Hong Kong dollars; Wuxi Bio (02269) rose by 10.54%, to 16.78 Hong Kong dollars.

On the news front, on October 18th, the National Medical Products Administration deliberated and passed the 'Biological Products Segmented Production Pilot Work Plan.' This pilot work is based on the current development status and regulatory practices of China's biomedical industry, actively responding to industry development needs, and exploring the segmented production of some innovative and clinically urgent biological products through commissioned production.

It is reported that the pilot work will focus on the segmented production of biological products in terms of evaluation and approval, enterprise quality management, post-market supervision, etc., to explore the establishment of a scientific and efficient segmented production full-process management system, promote the optimization of resource allocation in the biomedical industry, orderly integrate into the international industry chain, and achieve high-quality development.

In addition, Industrial Securities pointed out that China's CDMO industry competitiveness leads globally, and the emergence of new demand is expected to bring new development opportunities to the sector. Since the beginning of this year, domestic innovative support policies have emerged frequently, providing support for innovative drugs and medical devices, which are expected to bring performance flexibility to the sector. In terms of operation, some companies' orders in the first half of 24H1 have begun to show a recovery trend, looking ahead to the second half of the year, the order trend is expected to continue, and the performance is expected to improve compared to the previous period.